
    
      A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and
      tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against
      type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus
      erythematosus (SLE)
    
  